Literature DB >> 14730309

Agonist-independent modulation of N-type calcium channels by ORL1 receptors.

Aaron M Beedle1, John E McRory, Olivier Poirot, Clinton J Doering, Christophe Altier, Christian Barrere, Jawed Hamid, Joel Nargeot, Emmanuel Bourinet, Gerald W Zamponi.   

Abstract

We have investigated modulation of voltage-gated calcium channels by nociceptin (ORL1) receptors. In rat DRG neurons and in tsA-201 cells, nociceptin mediated a pronounced inhibition of N-type calcium channels, whereas other calcium channel subtypes were unaffected. In tsA-201 cells, expression of N-type channels with human ORL1 resulted in a voltage-dependent G-protein inhibition of the channel that occurred in the absence of nociceptin, the ORL1 receptor agonist. Consistent with this observation, native N-type channels of small nociceptive dorsal root ganglion (DRG) neurons also had tonic inhibition by G proteins. Biochemical characterization showed the existence of an N-type calcium channel-ORL1 receptor signaling complex, which efficiently exposes N-type channels to constitutive ORL1 receptor activity. Calcium channel activity is thus regulated by changes in ORL1 receptor expression, which provides a possible molecular mechanism for the development of tolerance to opioid receptor agonists.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14730309     DOI: 10.1038/nn1180

Source DB:  PubMed          Journal:  Nat Neurosci        ISSN: 1097-6256            Impact factor:   24.884


  50 in total

1.  Subtype-specific reduction of voltage-gated calcium current in medium-sized dorsal root ganglion neurons after painful peripheral nerve injury.

Authors:  J B McCallum; H-E Wu; Q Tang; W-M Kwok; Q H Hogan
Journal:  Neuroscience       Date:  2011-01-28       Impact factor: 3.590

Review 2.  Trafficking and stability of voltage-gated calcium channels.

Authors:  Brett A Simms; Gerald W Zamponi
Journal:  Cell Mol Life Sci       Date:  2011-10-02       Impact factor: 9.261

Review 3.  Calcium channel functions in pain processing.

Authors:  John Park; Z David Luo
Journal:  Channels (Austin)       Date:  2010-11-01       Impact factor: 2.581

Review 4.  G protein modulation of CaV2 voltage-gated calcium channels.

Authors:  Kevin P M Currie
Journal:  Channels (Austin)       Date:  2010-11-01       Impact factor: 2.581

5.  Inflammation reduces the contribution of N-type calcium channels to primary afferent synaptic transmission onto NK1 receptor-positive lamina I neurons in the rat dorsal horn.

Authors:  Beth K Rycroft; Kristina S Vikman; MacDonald J Christie
Journal:  J Physiol       Date:  2007-02-15       Impact factor: 5.182

6.  Alternative splicing of the Cav2.2 subunit: a change in N-type calcium channel activity for which purpose?

Authors:  Norbert Weiss
Journal:  J Physiol       Date:  2007-02-22       Impact factor: 5.182

7.  Silencing of the Cav3.2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception.

Authors:  Emmanuel Bourinet; Abdelkrim Alloui; Arnaud Monteil; Christian Barrère; Brigitte Couette; Olivier Poirot; Anne Pages; John McRory; Terrance P Snutch; Alain Eschalier; Joël Nargeot
Journal:  EMBO J       Date:  2004-12-16       Impact factor: 11.598

8.  Gi/o-coupled receptors compete for signaling to adenylyl cyclase in SH-SY5Y cells and reduce opioid-mediated cAMP overshoot.

Authors:  Erica S Levitt; Lauren C Purington; John R Traynor
Journal:  Mol Pharmacol       Date:  2010-11-22       Impact factor: 4.436

9.  Coupling specificity of NOP opioid receptors to pertussis-toxin-sensitive Galpha proteins in adult rat stellate ganglion neurons using small interference RNA.

Authors:  Wojciech Margas; Khaled Sedeek; Victor Ruiz-Velasco
Journal:  J Neurophysiol       Date:  2008-06-18       Impact factor: 2.714

Review 10.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.